PL2917231T3 - Lipopeptydy do stosowania w leczeniu chorób wątroby i chorób sercowo-naczyniowych - Google Patents

Lipopeptydy do stosowania w leczeniu chorób wątroby i chorób sercowo-naczyniowych

Info

Publication number
PL2917231T3
PL2917231T3 PL13796020T PL13796020T PL2917231T3 PL 2917231 T3 PL2917231 T3 PL 2917231T3 PL 13796020 T PL13796020 T PL 13796020T PL 13796020 T PL13796020 T PL 13796020T PL 2917231 T3 PL2917231 T3 PL 2917231T3
Authority
PL
Poland
Prior art keywords
diseases
lipopeptides
treating liver
cardiovascular
cardiovascular diseases
Prior art date
Application number
PL13796020T
Other languages
English (en)
Inventor
Volker CLEEVES
Stephan Urban
Ralf KUBITZ
Original Assignee
Ruprecht-Karls-Universität Heidelberg
Volker CLEEVES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ruprecht-Karls-Universität Heidelberg, Volker CLEEVES filed Critical Ruprecht-Karls-Universität Heidelberg
Publication of PL2917231T3 publication Critical patent/PL2917231T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
PL13796020T 2012-11-12 2013-11-12 Lipopeptydy do stosowania w leczeniu chorób wątroby i chorób sercowo-naczyniowych PL2917231T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261725144P 2012-11-12 2012-11-12
US201361859476P 2013-07-29 2013-07-29
EP13796020.9A EP2917231B1 (en) 2012-11-12 2013-11-12 Lipopeptides for use in treating liver diseases and cardiovascular diseases
PCT/EP2013/073600 WO2014072524A1 (en) 2012-11-12 2013-11-12 Lipopetides for use in treating liver diseases and cardiovascular diseases

Publications (1)

Publication Number Publication Date
PL2917231T3 true PL2917231T3 (pl) 2019-08-30

Family

ID=49674268

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13796020T PL2917231T3 (pl) 2012-11-12 2013-11-12 Lipopeptydy do stosowania w leczeniu chorób wątroby i chorób sercowo-naczyniowych

Country Status (8)

Country Link
US (4) US10413585B2 (pl)
EP (1) EP2917231B1 (pl)
CN (2) CN104781274B (pl)
DK (1) DK2917231T3 (pl)
ES (1) ES2728243T3 (pl)
HK (1) HK1214274A1 (pl)
PL (1) PL2917231T3 (pl)
WO (1) WO2014072524A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015014830A1 (en) * 2013-07-29 2015-02-05 Rupprecht-Karls-Universität Heidelberg Lipopetides for use in treating liver diseases and cardiovascular diseases
WO2016045642A1 (en) * 2014-09-28 2016-03-31 National Institute Of Biological Sciences, Beijing Polymeric bile acid derivatives inhibit hepatitis b and d virus and ntcp transport
PT3204030T (pt) * 2014-10-07 2022-08-05 Myr Gmbh Tratamento combinado de infeção por vhb e vhd
US10482551B2 (en) * 2015-08-10 2019-11-19 Google Llc Systems and methods of automatically estimating restaurant wait times using wearable devices
EP3189850A1 (en) 2015-12-16 2017-07-12 Ruprecht-Karls-Universität Heidelberg Liver targeting of cyclic pres-derived peptides of hbv
EP3181146A1 (en) 2015-12-16 2017-06-21 Ruprecht-Karls-Universität Heidelberg Cyclic ntcp-targeting peptides and their uses as entry inhibitors
US11633454B2 (en) 2016-05-30 2023-04-25 Shanghai Hep Pharmaceutical Co., Ltd. Compositions and methods for treating metabolic diseases
US10474800B2 (en) 2016-11-16 2019-11-12 Bank Of America Corporation Generating alerts based on vehicle system privacy mode
US10366219B2 (en) 2016-11-16 2019-07-30 Bank Of America Corporation Preventing unauthorized access to secured information using identification techniques
CN106749551A (zh) * 2016-12-30 2017-05-31 吉林大学 一种以多表位肽段组合抗原刺激免疫系统产生抗体的方法
EP3804750A1 (en) * 2019-10-10 2021-04-14 Universität Heidelberg Conjugate compounds for preventing and/or treating hbv and/or hdv infections, liver diseases and for targeting ntcp
CN111574594A (zh) * 2020-05-26 2020-08-25 成都圣诺生物制药有限公司 一种Bulevirtide的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009092396A1 (en) * 2008-01-25 2009-07-30 Universitätsklinikum Heidelberg Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors
WO2009092612A1 (en) 2008-01-25 2009-07-30 Universitätsklinikum Heidelberg Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as vehicles for the specific delivery of compounds to the liver
CN101240014B (zh) * 2008-03-07 2011-01-26 山东省科学院生物研究所 一种具有生理活性的脂肽复合物及其制备方法与应用
JP6486004B2 (ja) 2011-02-10 2019-03-20 ルプレヒト−カールス−ウニヴェルジテート ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ 疎水性修飾ペプチドおよび肝臓特異的標的化のためのその使用
WO2013159243A1 (en) * 2012-04-25 2013-10-31 National Institute Of Biological Sciences, Beijing Compositions and uses of functional receptor for hbv/hdv virus

Also Published As

Publication number Publication date
EP2917231B1 (en) 2019-03-06
US10413585B2 (en) 2019-09-17
US20240123025A1 (en) 2024-04-18
US10967044B2 (en) 2021-04-06
DK2917231T3 (da) 2019-06-11
US20160015775A1 (en) 2016-01-21
HK1214274A1 (zh) 2016-07-22
US20200384070A1 (en) 2020-12-10
ES2728243T3 (es) 2019-10-23
CN104781274B (zh) 2020-03-06
US20190151406A1 (en) 2019-05-23
WO2014072524A1 (en) 2014-05-15
CN104781274A (zh) 2015-07-15
EP2917231A1 (en) 2015-09-16
CN111499722A (zh) 2020-08-07

Similar Documents

Publication Publication Date Title
IL285985A (en) Therapeutic nuclease preparations and methods
HK1216176A1 (zh) 用於治療增殖性和自身免疫疾病的非對稱吡咯並苯並二氮雜卓二聚物
HK1214274A1 (zh) 用於治療肝臟疾病和心血管疾病的脂肽
ZA201305783B (en) Composition and methods for treating cardiovascular diseases
EP2884984A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
HK1201454A1 (en) Therapeutic agents and uses thereof
EP2830604A4 (en) COMPOSITIONS WITH SCOPOLAMINE AND KETAMINE FOR THE TREATMENT OF DEPRESSIONS
GB201120993D0 (en) Novel compounds and their use in therapy
DK3292875T3 (en) Compositions and methods for treating diseases
IL236399A0 (en) Polymerizable compositions and methods of use in vivo
GB201216649D0 (en) Agents and methods
EP2806894A4 (en) METHODS AND COMPOSITIONS FOR THERAPEUTICS
EP2817304A4 (en) NOVEL COMPOUNDS AND THEIR THERAPEUTIC USE
IL233875A (en) Preparation and use for the treatment of anal fissures
SG10201702375RA (en) Telomerase inhibitors for use in therapy
EP2895186A4 (en) THERAPEUTIC COMPOSITIONS AND RELATED METHODS
GB201218084D0 (en) Novel compounds and methods for use in medicine
EP2744786A4 (en) SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER
HK1207561A1 (en) Compositions and methods for treating hepatocellular cancer
EP2717900A4 (en) SCAFFOLD KINASE INTERACTION BLOCKADES AND ITS USE IN CANCER TREATMENT
GB201210664D0 (en) Means and methods for the reduction of photorespiration in crops